PI3K drives sarcoma growth through TAZ and YAP, and a two-drug combo hits both pathways
Sarcomas often lose PTEN, switching on PI3K. This study shows PI3K also controls TAZ/YAP, and that blocking TEAD and mTORC1 together works synergistically.
Summary
Sarcomas are varied cancers with few shared therapeutic targets. This study reports that PI3K signaling is frequently activated through PTEN loss, which the abstract places at 30%–60% of sarcomas. The authors identify TAZ and YAP as PI3K-regulated transcriptional coactivators that drive a gene-expression program necessary for tumor growth in a PI3K-driven sarcoma mouse model. This axis operates in parallel to PI3K/AKT/mTORC1 signaling. Combining the TEAD inhibitor IK-930 with the mTORC1 inhibitor everolimus reportedly reduced proliferation and anchorage-independent growth synergistically in PI3K-activated sarcoma cell lines at low, physiologically achievable doses, with synergy also reported in vivo. These preclinical findings support further investigation of combination therapy; they do not establish patient benefit.
Detailed Summary
Soft tissue sarcomas include more than 50 histological subtypes and have few shared therapeutic targets. The supplied introduction notes that PI3K signaling has been implicated in several sarcoma types despite a scarcity of mutations in PIK3CA and AKT1–3. It also describes modest efficacy from targeting mTORC1 in phase III sarcoma trials.
According to the abstract, PI3K signaling is frequently activated in sarcomas through PTEN loss, reported in 30%–60%. The authors identify TAZ and YAP as transcriptional coactivators regulated by PI3K. They report that these proteins drive a gene-expression program necessary for tumor growth in a PI3K-driven sarcoma mouse model.
The proposed PI3K/TAZ/YAP axis operates in parallel to the established PI3K/AKT/mTORC1 axis. This provides a rationale for jointly targeting the TAZ/YAP-TEAD interaction and mTORC1. The abstract reports that IK-930, a TEAD inhibitor, combined with everolimus, an mTORC1 inhibitor, synergistically diminished proliferation and anchorage-independent growth in PI3K-activated sarcoma cell lines at low, physiologically achievable doses. It also reports a synergistic effect in vivo.
The supplied excerpt includes the abstract and the beginning of the introduction, but not detailed methods or results. Sample sizes, exact doses, effect sizes, statistical analyses, and the design of the in vivo combination experiments therefore cannot be assessed from this material. The reported findings are preclinical and do not establish clinical efficacy or tolerability in patients.
Key Findings
- The abstract reports frequent PI3K activation through PTEN loss, with PTEN loss occurring in 30%–60% of sarcomas.
- TAZ and YAP are reported to be PI3K-regulated transcriptional coactivators that drive a gene-expression program necessary for tumor growth in a PI3K-driven sarcoma mouse model.
- The PI3K/TAZ/YAP axis is reported to operate in parallel to the PI3K/AKT/mTORC1 axis, providing a rationale for dual targeting.
- IK-930 plus everolimus reportedly synergistically diminished proliferation and anchorage-independent growth in PI3K-activated sarcoma cell lines at low, physiologically achievable doses.
- The abstract also reports combination synergy in vivo; detailed animal results and statistical analyses are not included in the supplied excerpt.
Methodology
The abstract describes mechanistic findings in a PI3K-driven sarcoma mouse model and combination-treatment experiments measuring proliferation and anchorage-independent growth in PI3K-activated sarcoma cell lines. It also reports in vivo combination synergy. The supplied excerpt does not include detailed methods, sample sizes, exact drug doses, synergy calculations, or statistical results.
Study Limitations
The supplied excerpt contains an abstract and only the beginning of the introduction, limiting assessment of experimental design, sample sizes, effect sizes, statistical robustness, and generalizability. The reported evidence comes from cell-line and mouse-model work and does not establish patient efficacy or safety. No conflicts-of-interest disclosure is included in the supplied excerpt.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: